GSKの空売り状況は、投資家がGSKの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

GSK (NYSE:GSK) 株価情報, 空売り情報

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.

GlaxoSmithKline

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

GSK PLC

Precidian ETFs Trust GSK plc ADRhedged

Goldseek Resources Inc Ordinary Shares

On Wednesday, the Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of respiratory syncytial virus (RSV) vaccines approved for adults 50-59 years of age at increased risk of RSV-associated lower <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">respiratory tract disease (LRTD)</a>.
In June 2024, ACIP postponed a vote on a recommendation for adults aged 50-59 at increased risk for RSV-LRTD until additional <a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39522040/cdc-advisor-panel-recommends-rsv-shots-in-us-for-people-above-75-years-analyst-says-decision-nega" rel="noreferrer noopener">data becomes available</a>.
The update includes Pfizer Inc.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Abrysvo (Respiratory Syncytial Virus Vaccine), which the U.S. Food and Drug Administration approved in October 2024 for the prevention of RSV-associated LRTD in adults aged 18 to 59 at increased <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41493556/fda-approves-pfizers-respiratory-syncytial-virus-vaccine-abrysvo-for-adults-below-60-years" rel="noreferrer noopener">risk of severe disease</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/25/04/44851905/trumps-new-order-targets-drug-pricing-transparency-and-medicare-cost-reduction" rel="noreferrer noopener">Trump&#8217;s New Order Targets Drug Pricing Transparency And Medicare Cost Reduction</a>
The recommendation also includes GSK plc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) Arexvy in adults aged 50-59 who are at increased risk <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44853850/arexvy-recommended-for-adults-aged-50-59-at-increased-risk-for-severe-respiratory-syncytial-virus-" rel="noreferrer noopener">for severe RSV disease</a>.
This expands on ACIP&#8217;s previous vote in June 2024 to recommend RSV vaccines for adults aged 60-74 who are at increased risk and all adults aged 75 and older.
Arexvy is indicated for the prevention of LRTD caused by RSV in individuals 60 years of age and older and individuals 50 through 59 years of age who are at increased risk for LRTD caused by RSV.
According to the CDC, between 15,000 &#8211; 20,000 RSV-associated hospitalizations occur annually in U.S. adults <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44852139/acip-votes-to-expand-recommendation-for-pfizers-rsv-vaccine-abrysvo-to-include-adults-aged-50-to-5" rel="noreferrer noopener">aged 50 &#8211; 59 years</a>.
A systematic review of studies in the U.S. shows that RSV is estimated to cause 42,000 hospitalizations each year in adults aged 50-64 years old.
GSK said the ACIP considered results from a phase 3 trial evaluating the immune response and safety of GSK&#8217;s RSV vaccine in adults aged 50-59, including those at increased risk for RSV-LRTD due to certain underlying medical conditions compared to older adults aged 60 years and older where efficacy has been demonstrated after a single dose of GSK&#8217;s RSV vaccine.
The updated recommendation does not benefit Moderna Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) mRNA-based RSV vaccine mRESVIA (mRNA-1345), which is currently approved for adults over 60 years.
William Blair notes Moderna shared Phase 3 data for mRNA-1345 in high-risk adults aged 18-59 at its 2024 R&amp;D Day event and has since submitted an application to the FDA for regulatory approval using a priority review voucher.&nbsp;The FDA <a target="_blank" href="https://investors.modernatx.com/news/news-details/2025/Moderna-Reports-Fourth-Quarter-and-Fiscal-Year-2024-Financial-Results-and-Provides-Business-Updates/default.aspx" rel="noreferrer noopener">has</a> accepted Moderna&#8217;s application and has assigned a PDUFA goal date of June 12, 2025.
Analyst Myles R. Minter highlights the Phase 3 trial of mRNA-1345 in over 1,000 high-risk individuals between ages 18 and 59. mRNA-1345 demonstrated non-inferior immunogenicity compared to adults age 60 or older for neutralizing antibodies against both RSV-A and RSV-B and a tolerable safety profile.
&#8220;If approved on time, we believe mRESVIA could be added to the updated age group recommendation during the scheduled June 25-26, 2025, ACIP meeting,&#8221; Minter said.
Price Action: PFE stock is up 1.07% 22.28, MRNA stock is down 2.30% at $24.62, and GSK stock is up 1.74% at $35.98 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44860903/eli-lillys-oral-glp-1-drug-orforglipron-hits-phase-3-goals-in-diabetes-trial-stock-shoots-higher" target="_blank" rel="noreferrer noopener">Eli Lilly&#8217;s Oral GLP-1 Drug Orforglipron Hits Phase 3 Goals In Diabetes Trial, Stock Soars</a></li>
</ul>
Photo by pedro7merino via Shutterstock

Biotech

Large Cap

News

Health Care

General

MRNA

US Advisory Panel Votes To Expand Recommendation For Pfizer, GSK's RSV Vaccines For Older Adults Below 60 Years

The U.K.&#8217;s Medicines and Healthcare products Regulatory Agency (MHRA) on Thursday authorized GSK plc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) Blenrep.
Blenrep&nbsp;is approved for the treatment of adults with multiple myeloma in combination with bortezomib plus dexamethasone (BVd) in patients who have received at least one prior therapy, and in combination with pomalidomide plus dexamethasone (BPd) in patients who have received at least one prior therapy including lenalidomide.&nbsp;
This&nbsp;U.K.&nbsp;regulatory authorization <a target="_blank" href="https://otp.tools.investis.com/generic/regulatory-story.aspx?cid=410&amp;newsid=1931677" rel="noreferrer noopener">marks</a> the first in the world for&nbsp;Blenrep&nbsp;in this treatment setting.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44496482/fda-approves-gsks-oral-antibiotic-for-urinary-tract-infections-for-females-aged-12-years-and-older" rel="noreferrer noopener">FDA Approves GSK&#8217;s Oral Antibiotic For Urinary Tract Infections For Females Aged 12 Years And Older</a>
Efficacy results from the pivotal DREAMM-7 and DREAMM-8 phase 3 trials in relapsed or refractory multiple myeloma support MHRA authorization of&nbsp;Blenrep&nbsp;combinations.
These include statistically significant and clinically meaningful progression-free survival (PFS) results for&nbsp;Blenrep&nbsp;combinations versus standards of care in both trials and overall survival (OS) in DREAMM-7.
DREAMM-7 and DREAMM-8 showed statistically significant and clinically meaningful PFS improvements for the Blenrep combinations compared to standard of care triplet combinations in the second line or later treatment of multiple myeloma.
In DREAMM-7, the&nbsp;Blenrep&nbsp;combination nearly tripled median PFS versus the daratumumab-based comparator (36.6 months versus 13.4 months, respectively.
<ul>
<li>DREAMM-7 also met the key secondary endpoint of OS, showing a statistically significant and clinically meaningful 42% reduction in the risk of death at a median follow-up of 39.4 months, favoring the Blenrep combination (n=243) versus the daratumumab-based <a href="https://www.benzinga.com/general/biotech/24/12/42420807/gsks-blood-cancer-drug-shows-improved-survival-compared-to-johnson-johnsons-darzalex" target="_blank" rel="noreferrer noopener">comparator (n=251)</a>.</li>
<li>The three-year OS rate was 74% in the Blenrep combination arm and 60% in the daratumumab combination arm. </li>
</ul>
In DREAMM-8, at a median follow-up of 21.8 months, the median PFS was not yet reached with the&nbsp;Blenrep&nbsp;combination compared to 12.7 months in the bortezomib combination.
Blenrep&nbsp;combinations are currently under review in 14 countries, including the&nbsp;U.S., with a Prescription Drug User Fee Act (PDUFA) date of 23 July 2025.
In 2022,&nbsp;GSK withdrew&nbsp;the U.S. marketing authorization for Blenrep following the FDA request, based on the previously announced outcome of the DREAMM-3 Phase 3 confirmatory trial,&nbsp;which did not meet the requirements of the FDA&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41986367/gsk-raises-prospects-for-withdrawn-blood-cancer-drug-blenrep-to-return-to-us-market-heres-why" rel="noreferrer noopener">Accelerated Approval regulations</a>.&nbsp;
Price Action: GSK stock is up 1.74% at $35.99 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44867490/evan-scott-takes-over-as-lockheed-martin-cfo-succeeding-jesus-jay-malave" target="_blank" rel="noreferrer noopener">Lockheed Martin Confirms New CFO, Evan Scott Takes Over For Jesus &#8216;Jay&#8217; Malave</a></li>
</ul>
Photo by HJBC via Shutterstock

UK Becomes First Country To Authorize Blenrep In Two Combo Regimens

<ul>
<li>Building on the last approval of Jemperli offering PFS benefit in dMMR/MSI-HC endometrial cancer, the expanded indication now offers survival benefit across the overall study population (dMMR/MSI-H and MMRp/MSS tumours)</li>
<li>Approval based on RUBY Part 1 trial, where Jemperli plus chemotherapy demonstrated a statistically significant and clinically meaningful 31% reduction in risk of death versus chemotherapy alone</li>
</ul>
MISSISSAUGA, ON, April 17, 2025 /CNW/ - GSK today announced that Health Canada has approved Jemperli (dostarlimab for injection) in combination with chemotherapy (carboplatin and paclitaxel) for the treatment of adult patients with primary advanced or first recurrent endometrial cancer who are candidates for systemic therapy.[1]&nbsp;This approval broadens the previous indication for Jemperli in combination with carboplatin and paclitaxel to include patients with mismatch repair proficient (MMRp)/microsatellite stable (MSS) tumours, which represents approximately 75% [2]&nbsp;of patients diagnosed with endometrial cancer and who have limited treatment options.

Global

GSK Announces Health Canada Expands Jemperli Plus Chemotherapy Approval To All Adult Patients With Primary Advanced Or First Recurrent Endometrial Cancer, As The First And Only Immuno-Oncology-Based Treatment To Show An Overall Survival Benefit For These Patients

GSK Plc Reveals That  CDC Advisory Panel Recommends PENMENVY for Inclusion in Adolescent Meningococcal Vaccination Schedule

Analyst Ratings

Trading Ideas

Watching GSK; Shares Move Higher, Goldman Sachs Suggesting Arexvy To Be Expanded By CDC; "Our Read Of The Slides Suggests The ACIP Voting To Expand Its Recommended Population For Arexvy To Those Aged 50-59 'At-Risk' Is Likely"

U.S.&nbsp;President Donald Trump, on Tuesday, disclosed plans for a "major tariff" on <a target="_blank" href="https://www.benzinga.com/topic/tariffs" rel="noreferrer noopener">foreign pharmaceuticals</a>.
"We're&nbsp;going to be announcing very&nbsp;shortly a major tariff on&nbsp;pharmaceuticals… when they hear that&nbsp;they will leave China, they&nbsp;will leave other places because… most of their product&nbsp;is sold here," Trump expressed at&nbsp;a National Republican <a target="_blank" href="https://www.benzinga.com/25/04/44708204/trump-hints-at-major-tariff-on-imported-pharmaceuticals-us-pharma-stocks-tumble-in-wednesday-pre-market" rel="noreferrer noopener">Congressional Committee&nbsp;dinner</a>.
He also told reporters on board his Air Force One plane that "pharma" tariffs would arrive "at a level that you haven't really seen before," saying these would be announced "in the near future," BBC <a target="_blank" href="https://www.bbc.com/news/articles/cedyylj1v32o" rel="noreferrer noopener">report</a> added.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44698325/trump-tariff-strategy-self-inflicted-market-debacle-says-wedbush-analyst" rel="noreferrer noopener">Trump Tariff Strategy Creates ‘Self-Inflicted Market Debacle': Analyst</a>
When President Trump announced tariffs last week, he excluded pharmaceuticals from the new tariffs, likely a relief for the industry under pressure following his prior comments suggesting a 25% tariff&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44652075/us-tariffs-spare-drugmakers-but-threaten-diabetes-device-industry" rel="noreferrer noopener">on pharmaceutical imports</a>.&nbsp;
On Wednesday, in a surprise announcement from President Donald Trump, a 90-day pause on tariffs for countries that have not retaliated <a target="_blank" href="https://www.benzinga.com/topic/tariffs" rel="noreferrer noopener">against U.S. trade measures.</a>
The news ignited a broad risk-on rally, catapulting major indices to multi-month highs and sending volatility plunging.
Trump's latest Truth Social post slammed China for showing "a lack of respect" and declared an immediate 125% tariff hike on Chinese goods.
"At some point, hopefully in the near future, China will realize that the days of ripping off the U.S.A. and other Countries is no longer sustainable or acceptable," he said.
He praised the over 75 countries that, in his words, "have not, at my strong suggestion, retaliated in any way, shape, or form."
As a reward, those countries would benefit from a temporary 10% reciprocal tariff and a 90-day pause on additional duties.
The biopharma industry has historically been shielded from tariffs, including during Trump's first term.
Although Trump didn't provide many details, his remarks have unsettled buyers, especially those who depend on medicines from India. India provides nearly half of all generic drugs used in the U.S., helping cut billions from healthcare costs.
The U.S. is a major market, buying about a third of India's $13 billion in yearly drug exports.
Indian drug companies warn that if tariffs are added, they'd have to raise prices—which could increase healthcare costs in the U.S.
Even though some companies like Cipla and Dr. Reddy's Laboratories Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDY#NYSE">RDY</a>) have factories in the U.S., most say it's too expensive to move production for low-profit generic drugs.
BofA Securities analyst says if the Trump administration plans to impose tariffs on the pharmaceutical industry, it would likely do so through a "Section 232 investigation" under the Trade Expansion Act of 1962 to determine whether importing certain goods threatens national security.
The typical timeline for a Section 232 investigation is about a year. If the same timeline applied here, tariffs on drug imports likely wouldn't take effect until late in the year—at the earliest.
It's unclear whether the Section 232 investigation into the drug industry is about to start, but based on recent comments from the administration, it seems possible. However, launching an investigation doesn't guarantee that tariffs will follow.
As the first quarter 2025 earnings season starts soon, analyst Tim Anderson says it will be worth watching whether companies discuss potential tariffs during earnings calls.
That said, any actual earnings impact likely wouldn't show up until sometime after 2025, which could leave investors with more questions than answers.
Wedbush analyst Daniel Ives <a target="_blank" href="https://www.benzinga.com/25/04/44698325/trump-tariff-strategy-self-inflicted-market-debacle-says-wedbush-analyst" rel="noreferrer noopener">on Tuesday wrote</a> that "saying we can just make this in the USA" understates how complex the supply chain in Asia really is—and how electronics, chips, semiconductors, hardware, and smartphones have been built for U.S. consumers over the past 30 years."
Shares of major drugmakers such as Gilead Sciences&nbsp;Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), Merck&nbsp;&amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), Eli Lilly&nbsp;And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), AstraZeneca&nbsp;Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), Roche&nbsp;Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>), Sanofi&nbsp;SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>), Novartis&nbsp;AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>), Argenx&nbsp;SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>), UCB&nbsp;SA (OTC:<a class="ticker" href="https://www.benzinga.com/stock/UCBJY#OTC">UCBJY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/UCBJF#OTC">UCBJF</a>), Novo Nordisk&nbsp;A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), Regeneron Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) GSK Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) and Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) fell on Wednesday, only reverse course later after the 90-day tariff pause.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44723376/goldman-sachs-scraps-recession-call-after-trumps-surprise-tariff-pause-as-wall-street-marks-strongest-day-since-2008" target="_blank" rel="noreferrer noopener">Goldman Sachs Scraps Recession Call After Trump's Surprise Tariff Pause As Wall Street Marks Strongest Day Since 2008</a></li>
</ul>
Photo by MargJohnsonVA via Shutterstock

Analyst Color

Government

Movers

ARGX

GILD

REGN

RHHBY

UCBJF

UCBJY

Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline

Under the terms of the agreement, ABL Bio will receive up to £77.1 million in upfront and near-term payments, including an immediate upfront payment of £38.5 million, research milestones and potential program expansion. In total, ABL Bio is eligible to receive up to £2.075 billion in research, development, regulatory and commercialization milestone payments&nbsp;across multiple potential programs. ABL Bio will receive tiered royalties on net sales if products are successfully commercialized. As part of the agreement, ABL Bio will transfer Grabody-B-related technology and know-how to GSK, while GSK will assume responsibility for preclinical and clinical development, manufacturing, and commercialization.

Contracts

ABL Bio Announced A Worldwide Licensing Agreement With GSK To Develop Medicines For Neurodegenerative Diseases By Utilizing ABL Bio's Blood-brain Barrier Shuttle Platform, Grabody-B, ABL Bio Will Receive Up To £2.075B Including £77.1M In Upfront And Near-term Payments

In the current session, GSK Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) is trading at $37.71, after a 3.33% decrease. Over the past month, the stock fell by 8.79%, and in the past year, by 10.58%. With performance like this, long-term shareholders are more likely to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2025/1743800417_0.png" alt="Past Year Chart" />

<h3>GSK P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 28.33 in the Pharmaceuticals industry, GSK Inc. has a lower P/E ratio of 24.27. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1743800417_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

A Look Into GSK Inc's Price Over Earnings

Researchers investigated whether the shingles (herpes zoster) vaccine can help prevent dementia. Previous studies suggest that certain herpes viruses may contribute to dementia, and vaccines might have <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">immune benefits</a>.
The new research, published on Wednesday, Nature analyzed data from 282,541 older adults in Wales and found that people who received the original shingles live virus vaccine were 20% less likely to develop dementia than non-vaccinated participants.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44395415/trump-administration-weighs-deep-cuts-to-domestic-hiv-prevention-programs-gilead-stock-slides" rel="noreferrer noopener">Trump Administration Weighs Deep Cuts To Domestic HIV Prevention Programs, Gilead Stock Slides</a>
Shingles, also known as herpes zoster, is&nbsp;a painful rash illness caused by the varicella-zoster virus, the same virus that causes chickenpox, which reactivates in the body after a person has had chickenpox.
The <a target="_blank" href="https://www.nature.com/articles/s41586-025-08800-x#Sec4" rel="noreferrer noopener">study</a> found that getting the zoster vaccine lowered the chance of being diagnosed with dementia over seven years by 3.5 percentage points, or about 20% relative risk reduction.
The protective effect was stronger in women than men. The findings were confirmed in another population (England and Wales) using death certificate data, showing fewer dementia-related deaths among vaccinated individuals.
Previous research in July 2024 <a target="_blank" href="https://www.nature.com/articles/s41591-024-03201-5" rel="noreferrer noopener">hinted</a> that the older live shingles vaccine might offer some protection, but that vaccine has been discontinued in favor of the recombinant version.
Researchers found that people who received the recombinant vaccine had a 17% longer period without a dementia diagnosis—equal to about 164 extra days dementia-free for those who eventually developed the condition.
The recombinant vaccine also appeared to reduce dementia risk more than flu and tetanus–diphtheria–pertussis vaccines. The effect was seen in both men and women but was stronger in women.
Last year, GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) revealed data from the ZOSTER-049 long-term follow-up phase 3 trial, which followed participants for up to approximately 11 years following initial vaccination with Shingrix <a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38289827/gsk-says-its-blockbuster-shingles-vaccine-shows-high-efficacy-even-after-10-years" rel="noreferrer noopener">(Recombinant Zoster Vaccine or RZV)</a>.&nbsp;
The final trial data demonstrate that RZV has maintained efficacy against shingles in adults over 50 for over a decade.&nbsp;
Shingrix sales for 2024 reached 3.36 billion pounds, down 2% (+1% at <a target="_blank" href="https://www.benzinga.com/25/02/43492835/gsk-launches-share-buyback-of-around-25-billion-after-better-than-expected-q4-earnings-raises-long-term-annual-sales-forecast-to-over-50-billion" rel="noreferrer noopener">constant currency)</a>.
Price Action: GSK stock is up 3.71% at $39.04 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44613813/sm-energy-to-see-q1-oil-output-rise-amid-uinta-expansion-says-analyst" target="_blank" rel="noreferrer noopener">SM Energy&#8217;s Near-Term Focus Centers On Debt Reduction Over Stock Buybacks: Analyst</a></li>
</ul>
Photo by HJBC via Shutterstock

New Study Shows Shingles Vaccine Linked To 20% Lower Dementia Risk, GSK Stock Pops

Politics

CVAC

NVAX

Trump Administration Health Agency Firings Include Staff Overseeing Bird Flu Response

GSK's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) short percent of float has fallen 5.49% since its last report. The company recently reported that it has 17.47 million shares sold short, which is 0.86% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.16 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>GSK Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743017414_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for GSK has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing GSK's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, GSK's peer group average for short interest as a percentage of float is 4.22%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into GSK's Recent Short Interest

<a href="https://www.wsj.com/health/pharma/pfizer-covid-vaccine-2020-election-probe-2f3ec247" title="https://www.wsj.com/health/pharma/pfizer-covid-vaccine-2020-election-probe-2f3ec247">https://www.wsj.com/health/pharma/pfizer-covid-vaccine-2020-election-probe-2f3ec247</a>

Legal

'U.S. Prosecutors Probe Tip About Timing Of Pfizer Vaccine; Claim Came To The U.S. Attorney's Office In Manhattan Via Pfizer Rival GSK' - WSJ

The US Food and Drug Administration (FDA) approved GSK plc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) Blujepa&nbsp;(gepotidacin) for the treatment of female adults (≥40 kg) and pediatric patients (≥12 years, ≥40 kg) with uncomplicated urinary <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">tract infections (uUTIs)</a>.
In a press release on Tuesday, the company said the U.S. commercial <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44484272/blujepa-gepotidacin-approved-by-us-fda-for-treatment-of-uncomplicated-urinary-tract-infections-uut" rel="noreferrer noopener">launch is planned in 2H 2025</a>.
UTIs are the most common infection in women, impacting up to 16 million women in the US annually.
The approval is based on results from the pivotal phase 3 EAGLE-2 and EAGLE-3 trials, which demonstrated non-inferiority to nitrofurantoin, one of the leading current standard of care options for uUTI, in female adults and pediatric patients with a confirmed uUTI.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44121869/gsks-once-daily-inhalers-for-smokers-lung-has-potential-benefits-independent-organization-report" rel="noreferrer noopener">GSK&#8217;s Once-Daily Inhalers For Smoker&#8217;s Lung Has Potential Benefits: Independent Organization Report</a>
In EAGLE-2, Blujepa demonstrated non-inferiority in therapeutic success, which occurred in 50.6% (162/320) of participants, compared to 47.0% (135/287) for nitrofurantoin.
In EAGLE-3,&nbsp;Blujepa&nbsp;demonstrated statistically significant superiority versus nitrofurantoin.
Therapeutic success occurred in 58.5% (162/277) of participants compared to 43.6% (115/264) for nitrofurantoin.
The development of&nbsp;Blujepa&nbsp;has been partially funded by federal funds from the US Department of Health and Human Services, the Administration for Strategic Preparedness and Response, the Biomedical Advanced Research and Development Authority, and federal funds awarded by the Defense Threat Reduction Agency.
Price Action: GSK stock is down 1.63% at $37.95&nbsp;at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/03/44493356/jinkosolar-cautious-on-2025-capacity-expansion-after-q4-loss-and-market-headwinds-details" target="_blank" rel="noreferrer noopener">JinkoSolar Cautious On 2025 Capacity Expansion After Q4 Loss And Market Headwinds: Details</a></li>
</ul>
Photo: Shutterstock

FDA Approves GSK's Oral Antibiotic For Urinary Tract Infections For Females Aged 12 Years And Older

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. and Shionogi as shareholders, is pleased to announce that APRETUDE (cabotegravir tablets and extended release injectable suspension) is now covered under the federal Non-Insured Health Benefits (NIHB) Program for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in at risk individuals who are HIV-1 negative.1
The Non-Insured Health Benefits (NIHB) Program provides eligible First Nations and Inuit people with coverage for a range of health benefits that are not otherwise covered through private, provincial, or territorial health insurance plans or social programs.2 In Canada approximately 10 per cent of all people living with HIV are Indigenous3, despite making up just five per cent of the country's population.4 Economic, social and systemic barriers, along with the lasting effects of racism and colonialism, all contribute to the disproportionate burden of HIV experienced by Indigenous people.5
The decision to reimburse APRETUDE through the NIHB Program will have a meaningful impact on HIV prevention efforts for eligible First Nations and Inuit people who are at-risk of HIV and could benefit from PrEP.

ViiV Healthcare Announces Reimbursement For APRETUDE For HIV-1 Pre-Exposure Prophylaxis Under The Non-Insured Health Benefits Program

<a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218230s000lbl.pdf" title="https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218230s000lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218230s000lbl.pdf</a>

GSK Gets FDA Approval Of Blujepa For Treatment Of Uncomplicated Urinary Tract Infections In Female Adults And Adolescents; This Is The First In A New Class Of Oral Antibiotic Treatment For uUTIs In Over 20 Years

The European Medicines Agency Has Accepted For Review Its Application To Expand The Use Of GSK's Nucala (Mepolizumab) As An Add-on Maintenance Treatment For Patients With Chronic Obstructive Pulmonary Disease With An Eosinophilic Phenotype

On Wednesday, US drug company Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) sold its entire stake in Haleon Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLN#NYSE">HLN</a>) to institutional investors and the consumer healthcare firm at 385 pence per share ($5.00).
Under the deal, Haleon agreed to purchase approximately 44 million ordinary shares at 385 pence from Pfizer off-market for an aggregate consideration of approximately 170 million pounds, or $220 million.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44311862/pfizers-direct-to-consumer-model-faces-scrutiny-from-us-senators" rel="noreferrer noopener">Pfizer&#8217;s Direct-To-Consumer Model Faces Scrutiny From US Senators&nbsp;</a>
Pfizer has <a href="https://www.londonstockexchange.com/news-article/market-news/pricing-of-offering-in-haleon-plc-by-pfizer-inc/16947121" target="_blank" rel="noreferrer noopener">sold</a> approximately 618 million ordinary shares in Haleon to institutional investors at 385 pence per share, raising gross sale proceeds of approximately 2.4 billion pounds, or $3.1 billion.
After the off-market purchase and Pfizer&#8217;s offering to institutional investors, Pfizer&#8217;s interest in Haleon&#8217;s issued ordinary shares with voting rights is <a target="_blank" href="https://www.londonstockexchange.com/news-article/HLN/update-on-off-market-purchase-alongside-pfizer/16947343" rel="noreferrer noopener">expected</a> to reduce from approximately 7.3% to nil.
Brian McNamara, CEO of Haleon, commented:&nbsp;&#8220;Today&#8217;s transaction is an important milestone for the business and marks Pfizer fully exiting its stake in Haleon, having been at 32% at the time of demerger in July 2022. Our participation in the offering is consistent with our disciplined capital allocation priorities, and supports our commitment to deliver attractive returns for shareholders, underpinned by a strong investment grade balance sheet. Nearly three years on from demerger, Haleon is in a position of strength and is well placed to capitalize on the significant opportunities ahead.&#8221;
Settlement of the offering is expected to occur on March 21.
In October 2024, Pfizer divested a $3.3 billion stake in&nbsp;Haleon, reducing its holding from 22.6% to 15% in the British <a target="_blank" href="https://www.benzinga.com/markets/equities/24/10/41112790/pfizer-divests-3-3b-stake-in-sensodyne-toothpaste-and-panadol-painkiller-maker-haleon" rel="noreferrer noopener">consumer healthcare company</a>.
In May 2024, GSK plc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>)&nbsp;confirmed&nbsp;the sale of 385.3 million shares in&nbsp;Haleon&nbsp;for $1.58 billion, fully exiting its <a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38895933/gsk-completely-exits-sensodyne-toothpaste-maker-haleon-in-1-6b-sale" rel="noreferrer noopener">position in Haleon</a>.&nbsp;
In the fourth-quarter earnings release, Haleon projects 2025 organic revenue to grow between 4% and 6%. Haleon expects organic revenue and operating profit growth to be weighted towards the s<a target="_blank" href="https://www.benzinga.com/general/health-care/25/02/44012867/sensodyne-toothpaste-maker-haleon-expects-profit-to-be-weighted-towards-second-half-of-2025" rel="noreferrer noopener">econd half of the year</a>.
Reuters notes that following Pfizer&#8217;s disposal, BlackRock Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>)&nbsp;unit will become Haleon&#8217;s largest shareholder with a more than 5% stake.
Price Action: HLN stock is down 0.05% at $10.28, and PFE stock is up 0.30% at $26.38 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/03/44396572/nvidia-introduces-new-ai-and-robotics-tools-at-gtc-powering-the-future-of-technology" target="_blank" rel="noreferrer noopener">NVIDIA Introduces New AI And Robotics Tools At GTC, Powering The Future Of Technology</a></li>
</ul>
Photo: Shutterstock

Pfizer Offloads Its Last 7% Stake In Consumer Health Haleon For Over $3 Billion

Gilead Sciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) stock is trading lower during the premarket trading session on Wednesday.
According to a Tuesday report in the Wall Street Journal, the Health and Human Services Department (HHS) is considering substantial reductions in federal funding for <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">domestic HIV prevention</a>.
According to people familiar with the matter, the WSJ reports that the plans could be announced within a day. However, they are not final and could still be changed or canceled.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44283318/gilead-presents-new-hiv-treatment-and-cure-research-data" rel="noreferrer noopener">Gilead Presents New HIV Treatment And Cure Research Data</a>
The Centers for Disease Control and Prevention (CDC) has a department focused on preventing HIV and other infectious diseases. It provides funding for state and local programs, including HIV tracking, syringe services, and community outreach, the WSJ writes.
Meanwhile, the Trump administration is planning significant staff cuts at the CDC as part of a broader reorganization, according to WSJ sources. The agency's structure makes it vulnerable to such changes since no single law defines its mission or programs.
Mitchell Warren, executive director of HIV prevention group AVAC, says the CDC's pre-exposure prophylaxis (PrEP) program could be reduced or cut. Launched last fall as a pilot program, it provides free medication to help prevent HIV.
PrEP&nbsp;is used by people who are HIV-negative and at high risk of being exposed to HIV infection.
In 2021, the FDA approved ViiV Healthcare's Apretude, the first injectable form of PrEP <a target="_blank" href="https://www.benzinga.com/24/12/42468692/gilead-unveils-new-yearly-hiv-injection-to-offer-hope-for-less-frequent-preventive-dosing" rel="noreferrer noopener">administered every two months</a>. ViiV Healthcare is owned by Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>), and Shinogi Ltd.
In 2023, the agency <a target="_blank" href="https://www.cdc.gov/nchhstp/budget-funding/index.html#cdc_program_funding_fund_by_cat-how-is-cdc-funding-used-for-hiv-viral-hepatitis-stis-tuberculosis-prevention" rel="noreferrer noopener">allocated</a> approximately $1.3 billion to combat HIV, viral hepatitis, sexually transmitted infections, and tuberculosis. Roughly 75% of those funds support state and local health departments, nonprofits, and other organizations engaged in disease prevention and outbreak response.
"No final decision on streamlining CDC's HIV Prevention Division has been made," the WSJ report <a target="_blank" href="https://www.wsj.com/health/healthcare/trump-administration-weighing-major-cuts-to-funding-for-domestic-hiv-prevention-8dcad39b" rel="noreferrer noopener">added</a>, citing the department's spokesman.
Gilead filed for regulatory approval of lenacapavir for PrEP (twice a year) last year and expects a potential <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43673047/gilead-ups-2025-outlook-eyes-lenacapavir-launch-for-hiv-prevention" rel="noreferrer noopener">commercial launch in 2025</a>.&nbsp;
Gilead also&nbsp;revealed that it is developing a once-yearly injectable formulation for lenacapavir. In its investor presentation, the company expects&nbsp;the pivotal Phase 3 pharmacokinetics study's first patient to be in 2025, and potential regulatory filings will <a target="_blank" href="https://www.benzinga.com/24/12/42468692/gilead-unveils-new-yearly-hiv-injection-to-offer-hope-for-less-frequent-preventive-dosing" rel="noreferrer noopener">begin in late 2027</a>.
Price Action: At the last check on Wednesday, GILD stock was down 2.02% at $108 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44393734/siemens-to-slash-6000-jobs-as-demand-slows-in-germany-and-china" target="_blank" rel="noreferrer noopener">Siemens To Slash 6,000 Jobs As Demand Slows In Germany And China</a></li>
</ul>

Media

Trump Administration Weighs Deep Cuts To Domestic HIV Prevention Programs, Gilead Stock Slides

<a href="https://www.bloomberg.com/news/articles/2025-03-14/us-measles-cases-so-far-this-year-surpass-total-for-all-2024" title="https://www.bloomberg.com/news/articles/2025-03-14/us-measles-cases-so-far-this-year-surpass-total-for-all-2024">https://www.bloomberg.com/news/articles/2025-03-14/us-measles-cases-so-far-this-year-surpass-total-for-all-2024</a>

'U.S. Measles Cases In 2025 Have Already Surpassed The Total For The Entire Year Of 2024' - Bloomberg

ViiV Healthcare announced Wednesday the latest findings from its <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">EMBRACE phase 2b study</a>.
The study found that N6LS (VH3810109 or VH109), given every four months in combination with monthly cabotegravir long-acting (CAB LA), kept viral levels suppressed in adults living with HIV who were already <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44280792/viiv-healthcares-investigational-broadly-neutralising-antibody-n6ls-successfully-maintains-viral-s" rel="noreferrer noopener">stable on treatment</a>.
These results were presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2025).
Results from the EMBRACE study at the six-month primary endpoint showed:
<ul>
<li>96% of participants receiving VH109 60mg/kg intravenously (IV) and 88% receiving VH109 3000mg subcutaneously (SC) with rHuPH20 maintained HIV-1 RNA levels below 50 copies/mL, compared to 96% in the standard-of-care group.</li>
</ul>
<ul>
<li>Overall, 4% of the IV group and 6% of the SC group had HIV-1 RNA levels of 50 copies/mL or higher when measured at month six, compared to none in the standard-of-care group.</li>
</ul>
<ul>
<li>VH109 was generally well tolerated, though infusion site reactions were more frequent with SC administration, occurring in 14% compared to none with IV administration.</li>
</ul>
<ul>
<li>ViiV Healthcare will progress a six-month IV formulation of VH109 in combination with CAB LA for further evaluation in an EMBRACE part two trial.</li>
</ul>
The company also presented data from two phase 2a proof-of-concept studies of investigational antiretroviral therapies, VH4524184 <a href="https://www.benzinga.com/pressreleases/25/03/b44261960/viiv-healthcare-showcases-leadership-in-long-acting-injectables-innovation-at-croi-2025-with-data-" target="_blank" rel="noreferrer noopener">(VH184) and VH4011499 (VH499)</a>.
Also Read: 
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/07/39915897/pfizer-and-gsks-viiv-healthcares-two-drug-hiv-treatment-matches-gileads-three-drug-combo-in-major" target="_blank" rel="noreferrer noopener">Pfizer And GSK&#8217;s ViiV Healthcare&#8217;s Two-Drug HIV Treatment Matches Gilead&#8217;s Three-Drug Combo In Major Trial</a></li>
</ul>
VH184 demonstrated potency at all doses. After 10 days of monotherapy, the average decreases were -1.17, -2.15, and -2.31 log10 copies/mL for the 10mg, 50mg, and 300mg doses, respectively.
<ul>
<li>The maximum viral load decline (-2.69 log10) was observed in the 300mg dose. Additionally, no drug-resistance mutations were observed at the end of the study.</li>
<li>Long-acting formulations of VH184 in adults without HIV are being evaluated in an ongoing phase 1 study.</li>
</ul>
<ul>
<li>The trial of VH499 showed that all oral doses (25mg, 100mg, and 250mg) led to a decrease in HIV-1 viral load ranging from -2.2 log10 copies/mL in the 250mg arm to -1.8 log10 copies/mL in the 25mg and 100mg arms. VH499 was well tolerated, with all adverse events being mild to moderate in severity.</li>
<li>There were no adverse events leading to withdrawal, and no serious adverse events were reported</li>
<li>On day 11, one individual on the 25mg dose developed a single mutation associated with reduced susceptibility to capsid inhibitors.</li>
</ul>
ViiV Healthcare is majority owned by GSK Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>), with Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and Shionogi as shareholders.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/management/25/03/44282015/cannabis-firm-cresco-labs-reports-mixed-q4-ceo-says-company-will-strategically-deploy-capital-to-create-growth-in-2025" target="_blank" rel="noreferrer noopener">Cannabis Firm Cresco Labs Reports Mixed Q4, CEO Says Company Will &#8216;Strategically Deploy Capital To Create Growth&#8217; In 2025</a></li>
</ul>

GSK, Pfizer's ViiV Healthcare Shows Strong HIV Viral Suppression In Latest Study

Press Releases

Shareholders that lost money on GSK plc(GSK) Urged to Join Class Action - Contact The Gross Law Firm to Learn More

GSK Investors Have Opportunity to Lead GSK plc Securities Fraud Lawsuit with the Schall Law Firm

Investors in GSK plc Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights – GSK

GSK plc Investors: Please contact the Portnoy Law Firm to recover your losses. April 7, 2025 Deadline to file Lead Plaintiff Motion.

Barbara Weber, M.D., Elected to ITM Supervisory Board

GSK Awards $2M in Grant Funding for Programs Supporting Adult Vaccination, Commits Additional $2M for 2025

Investing in the $532B Oncology Boom: Key Stocks Shaping the Future of Cancer Treatment

GSK's 5-in-1 Meningococcal Vaccine PENMENVY Receives Positive Recommendation from US Advisory Committee on Immunization Practices

AREXVY recommended for adults aged 50-59 at increased risk for severe respiratory syncytial virus (RSV) disease by US Advisory Committee on Immunization Practices

Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer's Disease

ADCT

ALEC

BNTX

DAWN

OSTX

RLAY

RVMD

TNGX

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

GSK

空売り

GSK (NYSE:GSK) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル